← Leaderboards
Chern-Hooi Lim
New Iridium
$1,724,922
Attributed
$1,724,922
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $766.4K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$1,724,922 · 2
By mechanism
R44$1,499,990 · 1
R43$224,932 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Novel Therapeutics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Novel TherapeuticsPropertyIndustrializationMetalsPhenoxazineProductionArchitectureGenerationsIridiumMetal ComplexPharmaceutical PreparationsPharmacologic SubstanceChemistryCommercializationCostCost EffectiveDrug SynthesisCouplingCatalysisDesignCatalystLightPerformancePublic Health
Grant awards (3)
Organic photoredox catalysts as sustainable and cost-effective replacement forprecious metal complexes in light-driven drug synthesis$733,549
R44 · FY2021 · GM · contact PI
Organic photoredox catalysts as sustainable and cost-effective replacement forprecious metal complexes in light-driven drug synthesis$766,441
R44 · FY2020 · GM · contact PI
Organic photoredox catalysts as sustainable and cost-effective replacement for precious metal complexes in light-driven drug synthesis$224,932
R43 · FY2019 · GM · contact PI